Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO to Present at Upcoming Investor Conferences

PR Newswire August 28, 2019

REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

PR Newswire August 27, 2019

REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

PR Newswire August 7, 2019

REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector

PR Newswire July 31, 2019

REGENXBIO To Host Conference Call on August 7 to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights

PR Newswire July 30, 2019

REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases

PR Newswire July 24, 2019

REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases

PR Newswire July 24, 2019

REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference

PR Newswire June 11, 2019

REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD

PR Newswire May 30, 2019

REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform

PR Newswire May 24, 2019

REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies

PR Newswire May 15, 2019

REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

PR Newswire May 8, 2019

REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

PR Newswire May 7, 2019

REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

PR Newswire April 30, 2019

REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer

PR Newswire April 17, 2019

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting

PR Newswire April 15, 2019

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire March 6, 2019

REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

PR Newswire February 27, 2019

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

PR Newswire February 20, 2019

REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists

PR Newswire February 14, 2019